Primary glioblastoma with oligodendroglial differentiation has better clinical outcome but no difference in common biological markers compared with other types of glioblastoma

Ross C. Laxton; Sergey Popov; Lawrence Doey; Alexa Jury; Ranj Bhangoo; Richard Gullan; Chris Chandler; Lucy Brazil; Gill Sadler; Ronald Beaney; Naomi Sibtain; Andrew King; Istvan Bodi; Chris Jones; Keyoumars Ashkan; Safa Al-Sarraj

doi:10.1093/neuonc/not125

Primary glioblastoma with oligodendroglial differentiation has better clinical outcome but no difference in common biological markers compared with other types of glioblastoma

Ross C. Laxton^*, Sergey Popov, Lawrence Doey, Alexa Jury, Ranj Bhangoo, Richard Gullan, Chris Chandler, Lucy Brazil, Gill Sadler, Ronald Beaney, Naomi Sibtain, Andrew King, Istvan Bodi, Chris Jones, Keyoumars Ashkan, Safa Al-Sarraj

^*Corresponding author for this work

Research output: Contribution to journal › Article › peer-review

14 Citations (Scopus)

Abstract

Background: Glioblastoma multiforme with an oligodendroglial component (GBMO) has been recognized in the World Health Organization classificationuhowever, the diagnostic criteria, molecular biology, and clinical outcome of primary GBMO remain unclear. Our aim was to investigate whether primary GBMO is a distinct clinicopathological subgroup of GBM and to determine the relative frequency of prognostic markers such as loss of heterozygosity (LOH) on 1p and/or 19q, O-6-methylguanine-DNA methyltransferase (MGMT) promoter methylation, and isocitrate dehydrogenase 1 (IDH1) mutation.

Methods: We examined 288 cases of primary GBM and assessed the molecular markers in 57 GBMO and 50 cases of other primary GBM, correlating the data with clinical parameters and outcome.

Results: GBMO comprised 21.5 of our GBM specimens and showed significantly longer survival compared with our other GBM (12 mo vs 5.8 mo, P .006); there was also a strong correlation with younger age at diagnosis (56.4 y vs 60.6 y, P .005). Singular LOH of 19q (P .04) conferred a 1.9-fold increased hazard of shorter survival. There was no difference in the frequencies of 1p or 19q deletion, MGMT promoter methylation, or IDH1 mutation (P .8, P 1.0, P 1.0, respectively).

Conclusions: Primary GBMO is a subgroup of GBM associated with longer survival and a younger age group but shows no difference in the frequency of LOH of 1p/19q, MGMT, and IDH1 mutation compared with other primary GBM.

Original language	English
Pages (from-to)	1635-1643
Number of pages	9
Journal	NEURO-ONCOLOGY
Volume	15
Issue number	12
DOIs	https://doi.org/10.1093/neuonc/not125
Publication status	Published - Dec 2013

Keywords

glioblastoma with an oligodendroglial component
histopathology
1p
19q
IDH1
MGMT
SUCCESSFUL CHEMOTHERAPY
MOLECULAR MARKERS
GRADE GLIOMAS
COMPONENT
SURVIVAL
TUMORS
MULTIFORME
MUTATIONS
PROGNOSIS

Access to Document

10.1093/neuonc/not125

Cite this

Laxton, R. C., Popov, S., Doey, L., Jury, A., Bhangoo, R., Gullan, R., Chandler, C., Brazil, L., Sadler, G., Beaney, R., Sibtain, N., King, A., Bodi, I., Jones, C., Ashkan, K., & Al-Sarraj, S. (2013). Primary glioblastoma with oligodendroglial differentiation has better clinical outcome but no difference in common biological markers compared with other types of glioblastoma. NEURO-ONCOLOGY, 15(12), 1635-1643. https://doi.org/10.1093/neuonc/not125

@article{6ee4da696eef46d6be5646130d0a0e1d,

title = "Primary glioblastoma with oligodendroglial differentiation has better clinical outcome but no difference in common biological markers compared with other types of glioblastoma",

abstract = "Background: Glioblastoma multiforme with an oligodendroglial component (GBMO) has been recognized in the World Health Organization classificationuhowever, the diagnostic criteria, molecular biology, and clinical outcome of primary GBMO remain unclear. Our aim was to investigate whether primary GBMO is a distinct clinicopathological subgroup of GBM and to determine the relative frequency of prognostic markers such as loss of heterozygosity (LOH) on 1p and/or 19q, O-6-methylguanine-DNA methyltransferase (MGMT) promoter methylation, and isocitrate dehydrogenase 1 (IDH1) mutation. Methods: We examined 288 cases of primary GBM and assessed the molecular markers in 57 GBMO and 50 cases of other primary GBM, correlating the data with clinical parameters and outcome. Results: GBMO comprised 21.5 of our GBM specimens and showed significantly longer survival compared with our other GBM (12 mo vs 5.8 mo, P .006); there was also a strong correlation with younger age at diagnosis (56.4 y vs 60.6 y, P .005). Singular LOH of 19q (P .04) conferred a 1.9-fold increased hazard of shorter survival. There was no difference in the frequencies of 1p or 19q deletion, MGMT promoter methylation, or IDH1 mutation (P .8, P 1.0, P 1.0, respectively). Conclusions: Primary GBMO is a subgroup of GBM associated with longer survival and a younger age group but shows no difference in the frequency of LOH of 1p/19q, MGMT, and IDH1 mutation compared with other primary GBM.",

keywords = "glioblastoma with an oligodendroglial component, histopathology, 1p, 19q, IDH1, MGMT, SUCCESSFUL CHEMOTHERAPY, MOLECULAR MARKERS, GRADE GLIOMAS, COMPONENT, SURVIVAL, TUMORS, MULTIFORME, MUTATIONS, PROGNOSIS",

author = "Laxton, {Ross C.} and Sergey Popov and Lawrence Doey and Alexa Jury and Ranj Bhangoo and Richard Gullan and Chris Chandler and Lucy Brazil and Gill Sadler and Ronald Beaney and Naomi Sibtain and Andrew King and Istvan Bodi and Chris Jones and Keyoumars Ashkan and Safa Al-Sarraj",

year = "2013",

month = dec,

doi = "10.1093/neuonc/not125",

language = "English",

volume = "15",

pages = "1635--1643",

journal = "NEURO-ONCOLOGY",

issn = "1522-8517",

publisher = "Oxford University Press",

number = "12",

}

Laxton, RC, Popov, S, Doey, L, Jury, A, Bhangoo, R, Gullan, R, Chandler, C, Brazil, L, Sadler, G, Beaney, R, Sibtain, N, King, A, Bodi, I, Jones, C, Ashkan, K & Al-Sarraj, S 2013, 'Primary glioblastoma with oligodendroglial differentiation has better clinical outcome but no difference in common biological markers compared with other types of glioblastoma', NEURO-ONCOLOGY, vol. 15, no. 12, pp. 1635-1643. https://doi.org/10.1093/neuonc/not125

TY - JOUR

T1 - Primary glioblastoma with oligodendroglial differentiation has better clinical outcome but no difference in common biological markers compared with other types of glioblastoma

AU - Laxton, Ross C.

AU - Popov, Sergey

AU - Doey, Lawrence

AU - Jury, Alexa

AU - Bhangoo, Ranj

AU - Gullan, Richard

AU - Chandler, Chris

AU - Brazil, Lucy

AU - Sadler, Gill

AU - Beaney, Ronald

AU - Sibtain, Naomi

AU - King, Andrew

AU - Bodi, Istvan

AU - Jones, Chris

AU - Ashkan, Keyoumars

AU - Al-Sarraj, Safa

PY - 2013/12

Y1 - 2013/12

N2 - Background: Glioblastoma multiforme with an oligodendroglial component (GBMO) has been recognized in the World Health Organization classificationuhowever, the diagnostic criteria, molecular biology, and clinical outcome of primary GBMO remain unclear. Our aim was to investigate whether primary GBMO is a distinct clinicopathological subgroup of GBM and to determine the relative frequency of prognostic markers such as loss of heterozygosity (LOH) on 1p and/or 19q, O-6-methylguanine-DNA methyltransferase (MGMT) promoter methylation, and isocitrate dehydrogenase 1 (IDH1) mutation. Methods: We examined 288 cases of primary GBM and assessed the molecular markers in 57 GBMO and 50 cases of other primary GBM, correlating the data with clinical parameters and outcome. Results: GBMO comprised 21.5 of our GBM specimens and showed significantly longer survival compared with our other GBM (12 mo vs 5.8 mo, P .006); there was also a strong correlation with younger age at diagnosis (56.4 y vs 60.6 y, P .005). Singular LOH of 19q (P .04) conferred a 1.9-fold increased hazard of shorter survival. There was no difference in the frequencies of 1p or 19q deletion, MGMT promoter methylation, or IDH1 mutation (P .8, P 1.0, P 1.0, respectively). Conclusions: Primary GBMO is a subgroup of GBM associated with longer survival and a younger age group but shows no difference in the frequency of LOH of 1p/19q, MGMT, and IDH1 mutation compared with other primary GBM.

AB - Background: Glioblastoma multiforme with an oligodendroglial component (GBMO) has been recognized in the World Health Organization classificationuhowever, the diagnostic criteria, molecular biology, and clinical outcome of primary GBMO remain unclear. Our aim was to investigate whether primary GBMO is a distinct clinicopathological subgroup of GBM and to determine the relative frequency of prognostic markers such as loss of heterozygosity (LOH) on 1p and/or 19q, O-6-methylguanine-DNA methyltransferase (MGMT) promoter methylation, and isocitrate dehydrogenase 1 (IDH1) mutation. Methods: We examined 288 cases of primary GBM and assessed the molecular markers in 57 GBMO and 50 cases of other primary GBM, correlating the data with clinical parameters and outcome. Results: GBMO comprised 21.5 of our GBM specimens and showed significantly longer survival compared with our other GBM (12 mo vs 5.8 mo, P .006); there was also a strong correlation with younger age at diagnosis (56.4 y vs 60.6 y, P .005). Singular LOH of 19q (P .04) conferred a 1.9-fold increased hazard of shorter survival. There was no difference in the frequencies of 1p or 19q deletion, MGMT promoter methylation, or IDH1 mutation (P .8, P 1.0, P 1.0, respectively). Conclusions: Primary GBMO is a subgroup of GBM associated with longer survival and a younger age group but shows no difference in the frequency of LOH of 1p/19q, MGMT, and IDH1 mutation compared with other primary GBM.

KW - glioblastoma with an oligodendroglial component

KW - histopathology

KW - 1p

KW - 19q

KW - IDH1

KW - MGMT

KW - SUCCESSFUL CHEMOTHERAPY

KW - MOLECULAR MARKERS

KW - GRADE GLIOMAS

KW - COMPONENT

KW - SURVIVAL

KW - TUMORS

KW - MULTIFORME

KW - MUTATIONS

KW - PROGNOSIS

U2 - 10.1093/neuonc/not125

DO - 10.1093/neuonc/not125

M3 - Article

SN - 1522-8517

VL - 15

SP - 1635

EP - 1643

JO - NEURO-ONCOLOGY

JF - NEURO-ONCOLOGY

IS - 12

ER -

Primary glioblastoma with oligodendroglial differentiation has better clinical outcome but no difference in common biological markers compared with other types of glioblastoma

Abstract

Keywords

Access to Document

Fingerprint

Cite this